targetsTarget

G-CSF receptor (CSF3R)

The receptor that tells the bone marrow to make neutrophils. Filgrastim and pegfilgrastim stimulate it to shorten the dangerous low-neutrophil period after chemotherapy, cutting the risk of febrile neutropenia.

The granulocyte colony-stimulating factor receptor on myeloid progenitors drives neutrophil production and release through JAK2 and STAT3 signalling. Recombinant G-CSF (filgrastim) and its long-acting pegylated form (pegfilgrastim) are given after myelosuppressive chemotherapy to shorten neutropenia and are recommended when the regimen carries a high risk of febrile neutropenia. They also mobilise stem cells before autologous transplantation. Activating CSF3R mutations define chronic neutrophilic leukaemia, which responds to the JAK inhibitor ruxolitinib.

G-CSF receptor (CSF3R): what it is and how drugs act on it · animated generic schematic, not to scale

Target · the protein and the cell it sits on
Drug · antibody, small molecule, cell or radioligand
Effect · signal, damage or kill

In plain words · The receptor that tells the bone marrow to make neutrophils. Filgrastim and pegfilgrastim stimulate it to shorten the dangerous low-neutrophil period after chemotherapy, cutting the risk of febrile neutropenia.

1 · What it is
The receptor that tells the bone marrow to make neutrophils. Filgrastim and pegfilgrastim stimulate it to shorten the dangerous low-neutrophil period after chemotherapy, cutting the risk of febrile neutropenia.
2 · What goes wrong in cancer
Cytokine receptor on neutrophil progenitors signalling through JAK2 and STAT3; agonised by recombinant G-CSF.
3 · How drugs use it
No product in this corpus aims at G-CSF receptor (CSF3R) yet. Drugs bind the molecule precisely: to switch it off, flag the cell for the immune system, or deliver a payload.